Archeus Technologies has received FDA clearance for its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer,…

Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to advance ART-101, a receptor-based targeting molecule, into…